Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease

Robert Wood Johnson Medical School, Neurology, 3 Cooper Plaza, Suite 320, Camden, NJ 08103, USA.
European journal of paediatric neurology: EJPN: official journal of the European Paediatric Neurology Society (Impact Factor: 2.3). 07/2010; 14(4):354-9. DOI: 10.1016/j.ejpn.2009.11.006
Source: PubMed


Our group has previously reported the first clinical application of lithium in a child affected by Canavan disease. In this study, we aimed to assess the effects of lithium on N-acetyl aspartate (NAA) as well as other end points in a larger cohort. Six patients with clinical, laboratory and genetic confirmation of Canavan disease were recruited and underwent treatment with lithium. The battery of safety and efficacy testing performed before and after sixty days of treatment included Gross Motor Function Testing (GMFM), Magnetic Resonance Imaging (MRI) Proton Magnetic Spectroscopy (H-MRS) as well as blood work. The medication was safe without any clinical or laboratory evidence for toxicity. Parental reports indicated improvement in alertness and social interactions. GMFM did not show statistically significant improvement in motor development. H-MRS documented an overall drop in NAA which was statistically significant in the basal ganglia. T1 measurements recorded on MRI studies suggested a mild improvement in myelination in the frontal white matter after treatment. Diffusion Tensor Imaging was available in two patients and suggested micro-structural improvement in the corpus callosum. The results suggest that lithium administration may be beneficial in patients with Canavan disease.

Download full-text


Available from: Dah-Jyuu Wang,
  • Source
    • "Increased taurine in the aspalacZ/lacZ brain may contribute to preservation of neuronal function via GABAA-mediated hyperpolarisation of thalamic relay neurons [22]. The profound increase of NAA in the CD brain is unique among neurological conditions and NAA-toxicity had been proposed as a reason for neuronal dysfunction [23], [24]. The efflux of NAA from neurons to the extracellular space is accompanied by a co-transport of water molecules, causing the interstitial pressure to rise [25]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Canavan Disease (CD) is a recessive leukodystrophy caused by loss of function mutations in the gene encoding aspartoacylase (ASPA), an oligodendrocyte-enriched enzyme that hydrolyses N-acetylaspartate (NAA) to acetate and aspartate. The neurological phenotypes of different rodent models of CD vary considerably. Here we report on a novel targeted aspa mouse mutant expressing the bacterial β-Galactosidase (lacZ) gene under the control of the aspa regulatory elements. X-Gal staining in known ASPA expression domains confirms the integrity of the modified locus in heterozygous aspa lacZ-knockin (aspa(lacZ/+)) mice. In addition, abundant ASPA expression was detected in Schwann cells. Homozygous (aspa(lacZ/lacZ)) mutants are ASPA-deficient, show CD-like histopathology and moderate neurological impairment with behavioural deficits that are more pronounced in aspa(lacZ/lacZ) males than females. Non-invasive ultrahigh field proton magnetic resonance spectroscopy revealed increased levels of NAA, myo-inositol and taurine in the aspa(lacZ/lacZ) brain. Spongy degeneration was prominent in hippocampus, thalamus, brain stem, and cerebellum, whereas white matter of optic nerve and corpus callosum was spared. Intracellular vacuolisation in astrocytes coincides with axonal swellings in cerebellum and brain stem of aspa(lacZ/lacZ) mutants indicating that astroglia may act as an osmolyte buffer in the aspa-deficient CNS. In summary, the aspa(lacZ) mouse is an accurate model of CD and an important tool to identify novel aspects of its complex pathology.
    PLoS ONE 05/2011; 6(5):e20336. DOI:10.1371/journal.pone.0020336 · 3.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Three viscoelastic models of the left-ventricular (LV) pumping function are proposed and compared with the classical elastance-resistance description starting from data measured on dogs: isovolumic pressure at a given preload together with a series of LV pressure and outflow curves with graded aortic occlusions. The comparison criterion takes into account descriptive ability, robustness of the estimates, and their physical interpretation. The analysis confirms the presence of both activation and deactivation phenomena. The dependence of stiffness and resistance on afterload agrees with known myocardial features and supports the local validity of the proposed models.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This clinical protocol describes virus-based gene transfer for Canavan disease, a childhood leukodystrophy. Canavan disease, also known as Van Bogaert-Bertrand disease, is a monogeneic, autosomal recessive disease in which the gene coding for the enzyme aspartoacylase (ASPA) is defective. The lack of functional enzyme leads to an increase in the central nervous system of the substrate molecule, N-acetyl-aspartate (NAA), which impairs normal myelination and results in spongiform degeneration of the brain. No effective treatment currently exists; however, virus-based gene transfer has the potential to arrest or reverse the course of this otherwise fatal condition. This procedure involves neurosurgical administration of approximately 900 billion genomic particles (approximately 10 billion infectious particles) of recombinant adeno-associated virus (AAV) containing the aspartoacylase gene (ASPA) directly to affected regions of the brain in each of 21 patients with Canavan disease. Pre- and post-delivery assessments include a battery of noninvasive biochemical, radiological, and neurological tests. This gene transfer study represents the first clinical use of AAV in the human brain and the first instance of viral gene transfer for a neurodegenerative disease.
    Human Gene Therapy 08/2002; 13(11):1391-412. DOI:10.1089/104303402760128612 · 3.76 Impact Factor
Show more